IceCure Positive Topline Results From ICE3 Cryoablation Breast Cancer Study

 

96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

• Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer
• Study represents largest cryoablation study of its kind in the U.S. for early-stage low-risk malignant breast tumors

https://www.biospace.com/article/releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-percent-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy/